The EORTC QLC-LC13 quality of life questionnaire for lung cancer patients. Validation study for Spain;El cuestionario de calidad de vida para cáncer de pulmón de la EORTC QLQ-LC13. Estudio de validación para nuestro país

Oncologia

Volumn 23, Issue 3, 2000, Pages 39-46

  Arraras, J I ^a   Pruja E ^a   Marcos, M ^a   Tejedor, M ^a   Illarramendi, J J ^a   Vera, R ^a   Arias, F ^a   Valerdi, J J ^a  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Lung cancer; Measurement; Quality of Life; Questionnaire

Indexed keywords

ARTICLE; CANCER SURVIVAL; DYSPNEA; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MEASUREMENT; PAIN ASSESSMENT; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; SCORING SYSTEM;

EID: 0034457850     PISSN: 03784835     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality of Life instrument for use in intentional clinical trials
2. The EORTC modular approach to Quality of Life assessment in Oncology
3. Quality of Life in clinical trials: Experience and perspective of the European Organization for Research and Treatment of Cancer
4. The EORTC approach to Quality of Life assessment: Guidelines for developing questionnaire modules
5. A modular approach to Quality of Life assessment in cancer clinical trials
6. The EORTC core Quality of Life questionnaire: Interim results of an international field study
7. The feasibility, validity and reliability of the EORTC QLQ-C30 in assessing the Quality Of Life of patients with symptomatic HIV infection or AIDS
8. The EORTC core quality of life questionnaire (QLQ-C30): Validity and reliability when analysed with patients treated with palliative radiotherapy
9. Comparison of 3 instruments (QLQ-C30, SF-36, QWB-7) measuring health related quality of life quality of well-being
10. Psychometric validation of the EORTC core quality of life questionnaire, 30 item version and a diagnosis-specific module for head and neck cancer patients
11. The EORTC QLQ-LC13: A modular supplement to the EORTC core Quality of Life questionnaire (QLQ-C30) for use in lung cancer clinical trials
12. The EORTC modular approach to Quality of Life assessment in Oncology: Un update
13. Quality of Life in patients with lung cancer. A review of literature from 1970 to 1995
14. Feasibility of Quality of Life assessment in a randomized phase III trial of small cell lung cancer. A lesson from the real world. The Swiss Group for Clinical Cancer Research SAKK
15. Assessment of Quality of Life using a daily diary card in a randomised trial of chemotherapy in small cell lung cancer
16. Quality of Life after surgical therapy of bronchogenic carcinoma
17. Quality versus quantity of life in the treatment of patients with advanced small cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. The Swiss Group for Clinical Cancer Research SAKK
18. Is quality of life predictive of survival of patients with advanced non-small cell lung carcinoma?
19. Quality of Life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only
20. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer
21. Randomized study of paclitaxelcisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
22. Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer
23. El cuestionario de Calidad de Vida de la EORTC QLQ-C30. Estudio estadístico de validación con una muestra españoola
24. Combined treatment with induction chemotherapy and hyperfractionated radiotherapy for the treatment of stage III non-small cell lung cancer
25. The use of nitrogen mustards in the palliative treatment of carcinoma